The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less
"First I’ll lose the weight, and then I’ll start exercising."It is a thought shared by almost anyone starting highly effective obesity medications...
Search results for "new obesity drug"
New Hope for MASH: Researchers Uncover Key to Reversing Liver Fibrosis
Researchers have unveiled findings that raise hopes for a future where a single pill could safely and effectively treat metabolic steatohepatitis and...
HK inno.N’s Obesity Drug Candidate Outperforms Wegovy in Head-to-Head Phase 2 Trial
HK inno.N announced on June 9 that its obesity drug candidate, ecnoglutide, demonstrated superior weight-loss efficacy...
South Korean Biotechs Race to Conquer the Untapped Global MASH Market
Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.
Daewoong Pharmaceutical Moves to Develop Once-Monthly GLP-1 Obesity Injection
Daewoong Pharmaceutical is teaming up with a biotech startup to develop an obesity treatment administered by injection...
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use
A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
Resistance in the Genes: Why Popular Obesity Drugs Don’t Work for Everyone
GLP-1 receptor agonists like Wegovy and Mounjaro have fundamentally reshaped the treatment of diabetes and obesity.
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...
GLP-1 Drugs and Bone Health: Studies Highlight Fracture Risks in Elderly Patients
The GLP-1 receptor agonist class of drugs, widely used for the treatment of obesity and type 2 diabetes, has...
Why ‘Elegant Dining’ Might Be the Secret to Appetite Control
If you typically rush through a sandwich at your desk or eat in a chaotic environment, you might be missing out on a...